Central Serous Chorioretinopathy: Long-Term Results After Photodynamic Therapy
DOI:
https://doi.org/10.48560/rspo.25892Keywords:
Chorioretinopathy/drug therapy, Photochemotherapy, Verteporfin/therapeutic useAbstract
Introduction: Central serous chorioretinopathy (CSC) is an idiopathic syndrome characterized by neurosensory detachments of the retina. Development of chronic CSC is an indication to treat, and ICGA-guided verteporfin photodynamic therapy has been shown to be very effective.
Our objective was to evaluate the 13-year follow-up of chronic CSC patients treated with standard-fluence PDT and to explore the long-term microstructural and vascular choroidal changes related to the disease and treatment.
Methods: Retrospective, interventional case-series analysis was conducted on 18 patients with cCSC, treated with standard PDT. Evaluations were performed every 3 months in the first year, every 6 months during the second year, and annually thereafter. All participants underwent a comprehensive ophthalmic examination. Retinal and choroidal imaging was performed with SD-OCT, SS-OCT, Optomap and OCTA.
Results: Twenty-three eyes of eighteen patients were included, with a mean age of 63.9±8.5 years. The mean follow-up was 15.8±1.4 years. The mean number of sPDT treatments was 1.2±0.4. At baseline, subretinal fluid was found in all eyes, RPE proliferation in 9.1% and atrophy in 9.1% of the eyes. There was not a statistically significant improvement in BCVA, despite an initial mean gain of 5.08±10.36 letters at month 12 (p<0.05), which decreased to 1.87±11.9 letters at the end of follow-up. In the final visit, only 3 eyes present subretinal fluid, 3 had fibrosis, but 15 (65.2%) showed atrophy. Central macular thickness reduced from 340.7±114.9 µm to 228.7±38.6 µm at end of the follow-up. The choroid of treated eyes was thicker but the choriocapillaris had less vascular flow compared to fellow-nontreated eyes at this point. Only one session of sPDT was needed in the 19 eyes, and 4 underwent 2 sessions.
Conclusion: ICGA-guided PDT full-fluence is a safe procedure, with no ocular or systemic adverse effects registered in our cohort. After 13 years, only 17.4% required 2 sessions. However, two-thirds of the cases presented atrophy in the last visit, which is probably related to the degenerative course of the disease and limited the initial visual acuity gains in the long term.
Downloads
References
Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow- up study. Retina. 2013;33:309-15. doi: 10.1097/IAE.0b013e3182670fbe. PubMed PMID: 23095766.
Rouvas A, Stavrakas P, Theodossiadis PG, Stamatiou P, Milia M, Giannakaki E, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22:417-22. doi: 10.5301/ejo.5000051.
Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye. 2013;27:612-20. doi: 10.1038/eye.2013.24.
Xu Y, Su Y, Li L, Qi H, Zheng H, Chen C. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy. Ophthalmologica. 2017;237:167-72. doi: 10.1159/000456676.
Liu J, Chen C, Li L, Xu Y, Yi Z, He L, et al. Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography. BMC Ophthalmol. 2020;20:402. doi: 10.1186/s12886-020-01674-9.
Liu B, Deng T, Zhang J. Risk factors for central serous chorioretinopathy: A Systematic Review and Meta-Analysis. Retina. 2016;36:9-19. doi: 10.1097/iae.0000000000000837.
Son BK, Kim K, Kim ES, Yu SY. Long-Term Outcomes of Full-Fluence and Half- Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Ophthalmologica. 2019;241:105-15. doi: 10.1159/000490773.
Alovisi C, Piccolino FC, Nassisi M, Eandi CM. Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. J Clin Med. 2020;9:9. doi: 10.3390/jcm9092734. van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced- settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2018;256:1395- 402.. doi: 10.1007/s00417-018-4003-z.
Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. PLoS One. 2017;12:e0181479. doi: 10.1371/journal.pone.0181479.
Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye. 2014;28:944-57. doi: 10.1038/eye.2014.134.
Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, et al. Long- term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251:1697-705. doi: 10.1007/s00417-013-2270-2..
Ma DJ, Park UC, Kim ET, Yu HG. Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy. PLoS One. 2018;13:e0202930. doi: 10.1371/journal.pone.0202930.
Hwang S, Noh H, Kang SW, Kang MC, Lee D, Kim SJ. Choroidal neovascularization secondary to photodynamic therapy for central serous chorioretinopathy: Incidence, Risk Factors, and Clinical Outcomes. Retina. 2021;41:1762-70. doi: 10.1097/iae.0000000000003067.
Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288-98. doi: 10.1097/00006982-200306000-00002.
Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, et al. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Am J Ophthalmol. 2016;170:91-9. doi: 10.1016/j.ajo.2016.07.026.
Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99:1070-7. doi: 10.1136/bjophthalmol-2014-305353.
Rouvas A, Nikita E, Chatziralli I, Ladas I, Androu A, Theodossiadis P. Long-term follow-up of standard photodynamic therapy with standardized small spot size for diffuse retinal pigment epitheliopathy. Eur J Ophthalmol. 2015;25:229-34. doi: 10.5301/ejo.5000541.
Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125:537-48. doi: 10.1016/j.ophtha.2017.09.028.
Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453-8. doi: 10.1136/bjo.87.12.1453.
Robertson DM. Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology. 1986;93:972-4. doi: 10.1016/s0161- 6420(86)33652-2.
von Winning CH, Oosterhuis JA, Renger-van Dijk AH, Hornstra-Limburg H, Polak BC. Diffuse retinal pigment epitheliopathy. Ophthalmologica. 1982;185:7-14. doi: 10.1159/000309216.
Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye. 2019;33:1035-43. doi: 10.1038/s41433-019-0381-7.
Park W, Kim M, Kim RY, Park YH. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half- fluence. Graefes Arch Clin Exp Ophthalmol. 2019;257:2155-61. doi: 10.1007/s00417-019-04426-8.
Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Kabadayi K. Comparison of half- dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2021;33:102081. doi: 10.1016/j.pdpdt.2020.102081. Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology. 1984;91:1544-8. doi: 10.1016/s0161-6420(84)34095-7.
Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953-61. doi: 10.1016/s0161-6420(13)31079-3.
Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214. doi: 10.1016/s0039-6257(00)00158-2.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23:752-63. doi: 10.1097/00006982-200312000-00002.
Tarantola RM, Law JC, Recchia FM, Sternberg P, Jr., Agarwal A. Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med. 2008;40:671-5. doi: 10.1002/lsm.20720.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Revista Sociedade Portuguesa de Oftalmologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
CC BY
Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.
To obtain the Conflict of Interest file (ICMJE template), click here
